TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
Status and phase
Conditions
Treatments
Details and patient eligibility
About
According to the BCLC staging system treatment recommendation, systemic treatment is recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for patients in this stage. Studies have shown that TACE combined with sorafenib therapy has shown effectiveness in the treatment of advanced liver cancer, and PD-1 inhibitors have also shown effectiveness in the treatment of advanced liver cancer. Therefore, in order to improve the survival benefit of BCLC stage C liver cancer patients, this clinical study was designed to evaluate the effectiveness and safety of TACE combined with sorafenib and tislelizumab in the treatment of BCLC stage C liver cancer patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age ≥18 years
- Child-Pugh score≤ 7
- HCC diagnosed by biopsy or by the noninvasive criteria of the Chinese Liver Cancer Guideline 2019
- the primary HCC being in BCLC C stage according to NCCN guideline
- No previous systemic therapy for HCC
Exclusion criteria
- Diffuse HCC
- Uncontrolled ascites of hepatic encephalopathy
- Prior liver transplantation
- Positive for human immunodeficiency virus
- Active gastric or duodenal ulcer
- Other uncontrolled comorbidities or malignancy
Trial design
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Tong-yin Zhu, MD; Jun-hui Sun, MD,PH.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal